Clinical trials
Completed Observational Uterine Cervical Dysplasia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 4 |
| GlaxoSmithKline | 3 |
| M.D. Anderson Cancer Center | 3 |
| STI-Medical Systems | 2 |
| University of Aarhus | 2 |
| Augusta University | 1 |
| Barzilai Medical Center | 1 |
| British Columbia Cancer Agency | 1 |
| Cathay General Hospital | 1 |
| Chulalongkorn University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uterine Cervical Dysplasia | 44 |
| Uterine Cervical Neoplasms | 28 |
| Acquired Immunodeficiency Syndrome | 5 |
| Papillomavirus Infections | 4 |
| Condylomata Acuminata | 2 |
| HIV Infections | 2 |
| Neoplasms | 2 |
| Precancerous Conditions | 2 |
| Atypical Squamous Cells of the Cervix | 1 |
| Carcinoma in Situ | 1 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.